95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1481602
This article is part of the Research Topic Biomarker Discovery and Therapeutic Innovations in Genito-Urinary Cancer Management View all 9 articles
Case report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion
Provisionally accepted- Jilin Cancer Hospital, Changchun, Jilin Province, China
Background: Inflammatory myofibroblastic tumor of the urinary bladder (IMTUB) is a rare tumor with low postoperative recurrence and metastasis. Due to the lack of clinical evidence, the optimal treatment paradigm for patients with IMTUB has not yet been established.Case presentation: We reported a case of a 55-year-old man who was diagnosed with bladder malignancy after transurethral resection of a bladder tumor, and then tumor metastasis was treated by traditional Chinese medicine. Following further disease progression, he was admitted to our hospital, where the diagnosis was revised to IMTUB with multiple metastases and TPM4-ALK fusion by computed tomography (CT) scan, pathological diagnosis, immunohistochemistry, and genetic testing. The patient subsequently received 225 mg ensartinib once daily. Symptoms improved and achieved partial response (PR) with acceptable toxicities.Conclusion: Ensartinib may provide a new therapeutic direction with promising efficacy and an acceptable safety profile for IMTUB with ALK fusion. Further clinical investigation is needed to identify its efficacy and safety.
Keywords: ensartinib, inflammatory myofibroblastic tumor, Urinary Bladder, Multiple metastases, TPM4-ALK
Received: 16 Aug 2024; Accepted: 03 Apr 2025.
Copyright: © 2025 Ren, Cheng, Chen, Sui, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fei Chen, Jilin Cancer Hospital, Changchun, Jilin Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.